Skip to content
CancerIndex

Publication

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.

Authors not recorded

Blood2012PMID 22490330stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (6)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 6

Curated evidence

Evidence citing this paper (7)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
22490330
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–7 of 7 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
DNMT3A Mutation1
(prognostic)Acute Myeloid LeukemiaCURATED_BROADERPrognosticBSupports Poor Outcome3accepted
EID188

Young AML patients (415 patients; <60 years old) with any DNMT3A mutation (n=96) have shorter overall survival and relapse-free survival than patients with wildtype DNMT3A.

PMID 22490330 · Ribeiro et al., 2012 · Open in CIViC

civic
DNMT3A R8825
(diagnostic)Acute Myeloid LeukemiaCURATED_BROADERDiagnosticBSupports Positive3accepted
EID4

Young AML patients (<60 years old) with DNMT3A mutations (60% of which were R882) were older in age, had higher white blood cell counts and had higher platelet counts than patients wildtype for DNMT3A… (full text at CIViC)

PMID 22490330 · Ribeiro et al., 2012 · Open in CIViC

civic
(prognostic)Acute Myeloid LeukemiaCURATED_BROADERPrognosticBDoes Not Support N/A4accepted
EID51

In young AML patients (<60 years old), DNMT3A mutation status (60% of which were R882) was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wild… (full text at CIViC)

PMID 22490330 · Ribeiro et al., 2012 · Open in CIViC

civic
〃Acute Myeloid LeukemiaCURATED_BROADERPrognosticBSupports Poor Outcome4accepted
EID67

In young AML patients (<60 years old), DNMT3A mutations were associated with significantly reduced overall survival and relapse free survival in patients wildtype for NPM1 and FLT3.

PMID 22490330 · Ribeiro et al., 2012 · Open in CIViC

civic
〃Acute Myeloid LeukemiaCURATED_BROADERPrognosticBSupports Poor Outcome3accepted
EID186

Complete remission rate was not different between young AML patients (<60 years old) with or without DNMT3A mutations (60% of which were R882).

PMID 22490330 · Ribeiro et al., 2012 · Open in CIViC

civic
〃Acute Myeloid LeukemiaCURATED_BROADERPrognosticBSupports Poor Outcome3accepted
EID189

Young AML patients (415 patients; <60 years old) with DNMT3A R882 mutations (n=58) have shorter overall and relapse-free survival than patients with wildtype DNMT3A.

PMID 22490330 · Ribeiro et al., 2012 · Open in CIViC

civic
FLT3 ITD1
(prognostic)Acute Myeloid LeukemiaCURATED_BROADERPrognosticBDoes Not Support N/A4accepted
EID52

In young AML patients (<60 years old), DNMT3A mutation status was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD.

PMID 22490330 · Ribeiro et al., 2012 · Open in CIViC

civic